c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook
Key Takeaways from the c-MET-NSCLC Pipeline Report
In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment
c-MET NSCLC Emerging Drugs Profile
JNJ-61186372: Janssen Research & Development, LLC
JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.
PLB1001 - Beijing Pearl Biotechnology Limited Liability Company
PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
c-MET NSCLC Companies
AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intramuscular
Intratumoral
Intravenous
Molecule Type
c-MET NSCLC Products have been categorized under various Molecule types such as
Gene therapies
Bispecific antibodies
Immunotherapies
Monoclonal antibodies
Small molecules
Product Type
Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the c-MET NSCLC Pipeline Report
Coverage- Global
c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
Mid Stage Products (Phase II)
Telisotuzumab: AbbVie
PLB1001: Beijing Pearl Biotechnology Limited Liability Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
JNJ-61186372: Janssen Research & Development, LLC
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
17 hours ago
- Winnipeg Free Press
Kellogg says it will remove artificial dyes from cereals by the end of 2027
NEW YORK (AP) — WK Kellogg Co. plans to remove artificial dyes from its breakfast cereals in the next two and a half years, according to the company and the attorney general of Texas. The maker of Froot Loops and Apple Jacks gave the timeline as U.S. food producers face increasing pressure from the U.S. government and consumers to phase out synthetic colorings from their products. Texas Attorney General Ken Paxton said Wednesday that Kellogg had signed an agreement assuring his office that the Michigan-based company would 'permanently remove toxic dyes' from its cereals by the end of 2027. Paxton launched an investigation earlier this year into whether Kellogg violated state consumer protection laws by continuing to use blue, red, yellow, green, and orange artificial dyes. Around the same time, U.S. health officials said that they would urge foodmakers to voluntarily work toward removing petroleum-based colors. Both Kellogg and General Mills, another major U.S. cereal maker, said they would. General Mills later joined Kraft Heinz, Nestle, Smuckers and some other food manufacturers in announcing target dates for making all their products without artificial dyes. But Paxton's office said Kellogg was the first to sign a 'legally binding' agreement. 'Following months of investigating and negotiating, I'm proud to officially say Kellogg's will stop putting these unhealthy ingredients in its cereals,' the attorney general said in a statement. Details about the terms of the agreement Kellogg signed, which is legally known as an assurance of voluntary compliance, were not immediately clear. The company did not comment on it directly when reached by The Associated Press on Thursday but said it appreciates 'the opportunity to work collaboratively with the Texas AG's office and share their focus on health and wellness.' Kellogg also pointed to its earlier commitment to phase out FD&C dyes, which are synthetic additives that the U.S. Food and Drug Administration approved for use in food, drugs and cosmetics. It said it already planned to stop launching new products with the dyes in January. Monday Mornings The latest local business news and a lookahead to the coming week. 'We have announced we are reformulating our cereals served in schools to not include FD&C colors by the 2026-27 school year,' Kellogg said in an emailed statement Thursday. By the end of 2027, 'we will completely remove FD&C colors from the small percentage of our foods that contain them today.' According to Kellogg's website, 85% of the cereal the company sells contains no FD&C colors — and none of its products have included Red No. 3 for years. Federal regulators banned that dye from food in January. Synthetic dyes have long been used to make brightly colored cereals, drinks, candies, baked goods and even products like cough syrup. But health advocates have called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that its currently approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' Pressure on the food industry has increased since Robert F. Kennedy Jr., an outspoken critic of such synthetic additives, became President Donald Trump's health secretary.
CTV News
18 hours ago
- CTV News
Sunningdale Road up for multi-million-dollar overhaul as London's north end grows at rapid pace
Improvements are on the way for a major east-west corridor in London's north end. Sunningdale Road West will soon be up for an overhaul, thanks to provincial government funding announced Thursday. 'This is a major corridor for anyone trying to get into the northwest part of the city,' commented Ward 7 Coun. Corrine Rahman. 'You think about all the development that's happened on Sunningdale Road. Fox Field, Sunningdale itself. And there's just so many people trying to get in and out of the area.' Rahman was on hand as a pair of provincial cabinet ministers announced $18.3 million in funding to upgrade Sunningdale Road West between Wonderland Road North and Village Walk Boulevard. The city says the improvements will allow for 5,000 new homes in the area. 'We need more homes built faster and smarter, because it takes too long and it costs too much to build housing. So that's why we're here today,' said Rob Flack, Elgin Middlesex London MPP and Minister of Municipal Affairs and Housing. SUNNINGDALE LONDON Doug MacRae, director, Transportation and Mobility, Mayor Josh Morgan, Kinga Surma, Minister of Infrastructure, Rob Flack, Member of Provincial Parliament for Elgin-Middlesex-London and Minister of Municipal Affairs and Housing, Corrine Rahman, Ward 7 councillor, on Aug. 14, 2025. (Bryan Bicknell/CTV News London) 'We hope to come back again, and we're very happy to see that you're moving on this funding very quickly,' added Kinga Surma, Minister of Infrastructure. According to the city, 'the improvements will include expanding the roadway from two to four lanes, adding new sidewalks, cycling lanes, lighting, and new stormwater infrastructure to improve drainage. A new bridge will be built for an expanded road crossing at Medway Creek, which will include a pathway connection along the creek.' Mayor Josh Morgan said the city can't take on projects such as this alone. 'We have to run balanced budgets every year. We have three pieces of our pie. We've got property taxes, user fees, and government grants. It means our provincial and federal partners are critical, critical to us actually supplying the infrastructure and services that we need,' said Morgan. The affected portion of Sunningdale is 2.2 kilometres in total. Construction is scheduled to get underway in spring of 2026, and it's expected to take two years. 'It's going to be painful. We're going to have to find other ways to get around and maneuver through the construction, but it will be well worth it in the end,' said Rahman.
Edmonton Journal
a day ago
- Edmonton Journal
Varcoe: From no business case to promoting LNG — gas producers welcome Ottawa's new support for growing sector
Like a stone skipping across calm water, it didn't take long for comments by Federal Natural Resources Minister Tim Hodgson touting the benefits of Canadian liquefied natural gas to ripple through the energy sector. Article content Canada's LNG is cleaner than competing U.S. suppliers and there are interested buyers for it, Hodgson said Tuesday on the Vassy Kapelos Show. Article content Article content Article content For Peyto Exploration & Development CEO Jean-Paul Lachance, having the federal minister in charge of energy actively promote LNG exports from Canada — and potentially include these initiatives on Ottawa's new major projects list under Bill C-5 — is telling. Article content 'The fact we're hearing that from our own government now, the federal government, is a very positive sign. It's a long way from, 'There's no business case for LNG,' which we heard from the previous government,' Lachance said in an interview Wednesday. Article content 'That gives me some confidence that there's going to be some support for LNG projects within Canada . . . It sends the right signal to the capital markets that we're open for business here.' Article content The Carney government recently passed Bill C-5 as it seeks to expedite approval of major infrastructure deemed to be of national significance. It's now consulting over which projects should make the cut. Article content Article content The Alberta government and many industry leaders are pushing for the list to include a major export pipeline to ship more oil to the West Coast, although no proponent has made a formal project proposal. Article content Article content The prospects for new LNG projects being included on the list appear strong and could provide a shot in the arm for western Canadian natural gas producers to attract new investment and boost output. Article content The colossal Shell-led LNG Canada terminal began moving first cargoes to customers this summer, launching a new energy export sector for the country.
